Skip to content

InsiderTradesSIGMA

RecommendationsTOP Fundamental picks TerminalNEW

Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FR US DE CH GB CA IT ES NL BE NO FI DK AU AT IE KR IN JP HK+ 8 markets

Recommendations
Fundamental picks
Terminal
Companies
Insiders
Performance
Backtest
Compare

Markets
Sectors
Top movers
Leaderboard
Clusters
Heatmap
Archive

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

Built bySimon Azoulay

All systems operational

Companies · Healthcare & Pharma · InsiderTrades Sigma · page 39

Sector3,940

Healthcare & Pharma

PDS Biotechnology Corp

PERDOCEO EDUCATION Corp

PHARMANUTRA AVVISO DI DEPOSITO DELLA LISTA PER LA NOMINA DEL COLLEGIO SINDACALE

PHARMANUTRA CDA DELIBERA DI CONVOCARE L’ASSEMBLEA ORDINARIA E STRAORDINARIA DELLA SOCIETÀ_BOARD OF DIRECTORS CONVENE THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING

PHARMANUTRA CS - DEPOSITO DEL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2023

PHARMANUTRA CS - DEPOSITO DEL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2023

PHARMANUTRA CS - PHARMANUTRA - PHN - CETILAR AL FIANCO DI FERNANDO ALONSO

PHARMANUTRA CS PHARMANUTRA - PHN - APPROVAZIONE BILANCIO DI SOSTENIBILITA' 2022

PHARMANUTRA CS PHARMANUTRA - PHN - APPROVAZIONE BILANCIO DI SOSTENIBILITA' 2022

PHARMANUTRA FIRST HALF 2023 RESULTS

PHARMANUTRA FIRST HALF 2023 RESULTS

PHARMANUTRA INTERIM MANAGMENT REPORT AS OF 30 SEPTEMBER 2023

PHARMANUTRA INTERIM MANAGMENT REPORT AS OF 30 SEPTEMBER 2023

PHARMANUTRA NOTICE OF FILING OF THE LIST FOR THE APPOINTMENT OF THE BOARD OF STATUTORY AUDITORS

PHARMANUTRA PHARMANUTRA

PHARMANUTRA PHARMANUTRA - PHN - DEPOSITO DOCUMENTAZIONE PER ASSEMBLEA DEGLI AZIONISTI

PHARMANUTRA PHARMANUTRA - PHN - ORIENTAMENTI DEL CDA AGLI AZIONISTI SULLA FUTURA DIMENSIONE E COMPOSIZIONE DEL NUOVO CDA - NOMINA DELL’INVESTOR RELATOR

PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025

PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025

PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025

PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025

PHARMANUTRA PHARMANUTRA PHN - RICAVI PRELIMINARI 2025

PHARMANUTRA PHARMANUTRA PHN - RICAVI PRELIMINARI 2025

PHARMANUTRA PHARMANUTRA S.P.A.: AL VIA IN MESSICO LA DISTRIBUZIONE DEI COMPLEMENTI NUTRIZIONALI A BASE DI FERRO

PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025

PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025

PHARMANUTRA PHARMANUTRA S.P.A.: FIRST SIGNIFICANT SALES RESULTS IN CHINA

PHARMANUTRA PHARMANUTRA S.P.A.: LE NOVITA SUI MERCATI ESTERI

PHARMANUTRA PHARMANUTRA S.P.A.: NEWS AND UPDATES ON FOREIGN MARKETS

PHARMANUTRA PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO

PHARMANUTRA PHARMANUTRA_PR

PHARMANUTRA PHN

PHARMANUTRA PHN - RICAVI PRELIMINARI 2023

PHARMANUTRA PR - PHARMANUTRA - PHN - CETILAR SIDE BY SIDE WITH FERNANDO ALONSO

PHARMANUTRA PR - PHN PRELIMINARY REVENUES 2023

PHARMANUTRA PR - PHN PRELIMINARY REVENUES 2023

PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT

PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT

PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023

PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023

PHYSITRACK PLC *

← PreviousPage 39 of 79Next →